Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine · 12.02.2026 · 15 (4) · 1434
DOI: 10.3390/jcm15041434 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.02.2026. Verfasst von William A Barzola-Farfán und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima 15072, Peru. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This investigation compared the efficacy and safety of fexuprazan 40 mg and esomeprazole 40 mg in patients with acid reflux-related disorders, including erosive esophagitis (EE) and laryngopharyngeal reflux disease (LPRD).
Methods
A systematic search was conducted across five databases until January 2025. Primary outcomes included esophageal lesion healing, complete resolution of symptoms (CRS), and 24 h symptom-free days. Meta-analyses used random-effects models with the inverse variance method. The Risk of Bias 2.0 tool and the certainty of evidence (CoE) using GRADE methodology were assessed.
Results
Three randomized controlled trials (n = 695) conducted in Asian countries were included. Fexuprazan may have little to no effect compared to esomeprazole on EE healing rate at 4 weeks (RR 1.02, 95% CI 0.93 to 1.12, I2 = 0%, n = 2 studies, CoE very low) and 8 weeks. No significant differences were found between treatments regarding CRS at 1 week (RR 1.29; 95% CI: 0.84 to 1.99; I2 = 0%; n = 2 studies; CoE very low) and 8 weeks, or in the 24 h symptom-free days at 1 week (MD 2.67 days, 95% CI −2.76 to 8.10, I2 = 41%, n = 2 studies, CoE very low) and 8 weeks. Fexuprazan also showed little to no effect on treatment-emergent adverse events (RR 1.00, 95% CI 0.83 to 1.20, I2 = 0%, n = 3 studies, CoE very low). Nonetheless, the evidence for all outcomes was rated as very uncertain.
Conclusions
Fexuprazan 40 mg may provide similar efficacy compared to esomeprazole 40 mg in EE, with a comparable safety profile to esomeprazole in EE and LPRD patients. However, the evidence is highly uncertain, requiring further studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud, Lima 15072, Peru.
- Tau Clinical Research Methods Network, Trujillo 13001, Peru.
- Vicerrectorado de Investigación, Universidad Señor de Sipan, Chiclayo 14001, Peru.
ORCID-Profile: William A Barzola-Farfán, Carlos Quispe-Vicuña
Zitieren
APA
Barzola-Farfán, W. A., Quispe-Vicuña, C., Rivera-Lozada, O., Bonilla-Asalde, C., & Barboza, J. J. (2026). Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 15(4), 1434. https://doi.org/10.3390/jcm15041434
Vancouver
Barzola-Farfán WA, Quispe-Vicuña C, Rivera-Lozada O, Bonilla-Asalde C, Barboza JJ. Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2026;15(4):1434. doi:10.3390/jcm15041434
BibTeX
@article{BarzolaFarfn2026,
author = {Barzola-Farfán, William A and Quispe-Vicuña, Carlos and Rivera-Lozada, Oriana and Bonilla-Asalde, Cesar and Barboza, Joshuan J},
title = {Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {4},
pages = {1434},
doi = {10.3390/jcm15041434}
}
EUVIMED